Nasdaq
$2.91▼ 0.17%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $143.4MShares out 49.3M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
26- 10.14After-hours26.10.15 05:05DEF 14AOther#●●●#●●●
Entera Bio Ltd.
Entera Bio will hold a Special Meeting of Shareholders on November 24, 2026, to vote on eight proposals, including an increase of 13,937,915 shares issuable under its 2018 Equity Incentive Plan. The meeting primarily seeks approval for one-time equity grants to management and directors, following the company's approximately $275 million private placement completed in July 2026.…more
$2.91-0.17%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.6Pre-market26.10.06 21:008-KKey event
Entera Bio Ltd.
Entera Bio announced the appointment of biopharmaceutical executive Laura Hamill to its Board of Directors, effective December 1, 2026. Ms. Hamill, formerly of Gilead Sciences and Amgen, will succeed outgoing director Yonatan Malca.…more
$2.91-0.17%vs prev closeView filingShare - 9.23After-hours26.09.24 05:05PRE 14AOther
Entera Bio Ltd.
Entera Bio will hold a Special Meeting of Shareholders on November 24, 2026, to approve an increase of 13,937,915 shares under its 2018 Equity Incentive Plan and authorize one-time equity grants for management. The company previously raised approximately $275 million in a July 2026 private placement, securing funding for its EB613 Phase 3 program and extending its cash runway through 2030. These proposals are part of the governance and compensation agreements established during the financing.…more
$2.91-0.17%vs prev closeView filingShare
25 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.13Pre-market26.10.13 20:00#●●●#●●●
Entera Bio Presents EB613 Phase 2 Data and Phase 3 Study Design for Osteoporosis…more
Entera Bio reported positive post-hoc Phase 2 data for its oral osteoporosis candidate EB613 and outlined the design for its upcoming Phase 3 study. These findings remain in the clinical development stage and require further regulatory validation and commercial proof.…more
$2.91-0.17%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.8Pre-market26.10.08 21:00
●●●●●●●● ●●●●● ●●●●●●
Entera Bio announced it will present the clinical study design for its Phase 3 trial of EB613 at the upcoming ASBMR 2026 Annual Meeting. This presentation focuses on academic methodology and does not represent a material regulatory or commercial milestone.…more
$2.91-0.17%vs prev close - 8.27Regular26.08.27 22:44
●●●●●●●● ●●●●● ●●●●●●
Entera Bio announced that its CEO will participate in several upcoming investor conferences this fall. This is a routine corporate communication and does not provide immediate material impact on the stock price.…more
$2.91-0.17%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report